Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...

Fortinet, AppLovin, Airbnb, Duolingo and more stock were making big moves Thursday after the companies reported quarterly ...

Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...

U.S. stock futures rose on Thursday after ending higher on Wednesday. Futures of major benchmark indices were up.

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

O'Reilly Automotive Inc. is suing the three major pharmacy benefit managers in the U.S., as well as the three major insulin manufacturers.

The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year or so.

Originally developed to treat type 2 diabetes and medical obesity, GLP-1 receptor agonists like tirzepatide and semaglutide ...

New evidence of effectiveness is cause to drop a Biden restriction on Medicare coverage for anti-amyloid treatments.